Gain Therapeutics Presents GT-02287 Clinical Data at AD/PD 2026 Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2026
0mins
Should l Buy GANX?
Gain Therapeutics announced the presentation of an oral presentation and poster at AD/PD 2026 International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders, being held March 17-21, in Copenhagen, Denmark. The oral presentation outlined new clinical and biomarker data from the Phase 1b clinical study of GT-02287 further supporting disease-modifying potential in both idiopathic and GBA1 Parkinson's disease. The Company also presented a poster outlining preclinical data from a structurally distinct chemical series of allosteric glucocerebrosidase modulators, which are ready for IND-enabling studies for the treatment of Parkinson's disease an other neurological disorders. The oral presentation, entitled, "An Open-Label Phase 1b Study of GT-02287 in Parkinson's Disease," was delivered on-site by the Company's Chief Medical Officer, Jonas Hannestad. Data on safety, tolerability, biomarkers, and clinical scores from the completed Part 1 of the study support continued development of GT-02287 for PD. Of the 19 participants who completed dosing in Part 1, 16 chose to continue in the ongoing nine-month extension, further supporting the tolerability of GT-02287. A Data Monitoring Committee meeting on March 5, 2026, concluded that the study should continue without any changes. The poster, titled, "Novel Allosteric GCase Modulators, Different From the Clinical Stage GT-02287, for the Treatment of Parkinson's Disease," was presented on-site by the Company's Head of Research Ana Maria Garcia-Collazo. The new, orally available, brain penetrant chemical series - led by GT-04686 - demonstrates potential for future clinical development, as evidenced by restoration of key biological activities that are impaired in Parkinson's disease. These findings together support advancement of this novel chemical series towards the clinic and the potential to be developed for PD and other indications where GCase deficiency is implicated.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GANX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GANX
Wall Street analysts forecast GANX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.890
Low
5.00
Averages
7.50
High
10.00
Current: 1.890
Low
5.00
Averages
7.50
High
10.00
About GANX
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gain Therapeutics to Present Updates on Parkinson's Disease Candidate GT-02287
- Key Presentation: Gain Therapeutics will deliver an oral presentation on May 22, 2026, at the 3rd International GBA1 Meeting in Phoenix, Arizona, highlighting updates on its Parkinson's disease candidate GT-02287, showcasing the company's ongoing innovation in neurodegenerative diseases.
- Drug Mechanism and Effects: GT-02287 is an orally administered small molecule designed to restore the function of glucocerebrosidase (GCase) impaired in GBA1-associated and idiopathic Parkinson's disease, with preclinical studies showing improved GCase activity, reduced neuroinflammation, and protective effects on motor function.
- Clinical Trial Progress: Early Phase 1 clinical data indicate favorable safety and CNS exposure in healthy volunteers, with significant increases in GCase activity at therapeutic doses; the drug is currently being evaluated in a Phase 1b trial allowing treatment for up to 12 months in Parkinson's disease patients.
- Market Performance: GANX stock has traded between $1.41 and $4.34 over the past year, currently priced at $2.03, reflecting a 7.41% increase, indicating positive market sentiment towards its drug development progress.
See More
Gain Therapeutics Updates on GT-02287 for Parkinson's Disease
- Clinical Trial Progress: Gain Therapeutics is currently conducting a Phase 1b clinical trial for GT-02287 across seven sites in Australia, primarily assessing its safety and tolerability in Parkinson's disease patients, which is expected to provide crucial data for the drug's market potential.
- Innovative Drug Mechanism: As an orally administered small molecule, GT-02287 restores enzyme function impaired by GBA1 gene mutations, with preliminary data showing significant improvements in motor function and behavioral performance in animal models, indicating a potential disease-modifying effect.
- Funding Support: The project has received funding from The Michael J. Fox Foundation and other organizations, highlighting its recognition in Parkinson's disease treatment research and potentially accelerating clinical progress.
- International Conference Participation: The company will present an oral update on GT-02287 at the International GBA1 Meeting on May 22-23, 2026, further enhancing its visibility and influence in the biotechnology sector.
See More
Gain Therapeutics Reports FY EPS Beat
- Earnings Performance: Gain Therapeutics reported a FY GAAP EPS of -$0.61, beating expectations by $0.03, indicating gradual financial improvement despite ongoing challenges.
- Cash Position: As of December 31, 2025, the company held $20.8 million in cash, cash equivalents, and marketable securities, doubling from $10.4 million a year earlier, showcasing significant progress in financial management.
- Market Reaction: Although still in a loss position, the earnings beat may boost investor confidence, likely leading to a positive impact on stock price and attracting more attention and investment.
- Future Outlook: With increased cash reserves, Gain Therapeutics is positioned to enhance R&D investments, driving the development and marketing of new drugs, thereby strengthening its competitive edge in the biopharmaceutical sector.
See More
GAIN THERAPEUTICS INC Reports $20.2 Million Net Loss for 2025, Equivalent to $0.61 Per Share
- Financial Performance: Gain Therapeutics reported a net loss of $20.2 million for the year 2025, equating to a loss of $0.61 per share.
- Market Impact: The financial results may influence investor sentiment and the company's stock performance in the upcoming quarters.
See More
Gain Therapeutics Attends J.P. Morgan Healthcare Conference to Showcase GT-02287
- Conference Participation: Gain Therapeutics will attend several key forums during the J.P. Morgan Healthcare Conference from January 11 to 14, showcasing its latest advancements in Parkinson's disease treatment to enhance its visibility in the biotech industry.
- Drug Development: The lead drug candidate GT-02287 is currently undergoing a Phase 1b clinical trial primarily assessing its safety and tolerability in Parkinson's patients, which is expected to lay the groundwork for future market introduction.
- Funding Support: Gain's GT-02287 program has received funding from The Michael J. Fox Foundation and the European Union, indicating its development potential and market recognition, which may accelerate clinical progress.
- Technology Platform: Gain leverages its advanced Magellan™ platform to expedite drug discovery, focusing on developing treatments for neurodegenerative diseases, showcasing the company's innovative capabilities in the biotech sector.
See More
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
See More
Gain Therapeutics to Present Updates on Parkinson's Disease Candidate GT-02287
- Key Presentation: Gain Therapeutics will deliver an oral presentation on May 22, 2026, at the 3rd International GBA1 Meeting in Phoenix, Arizona, highlighting updates on its Parkinson's disease candidate GT-02287, showcasing the company's ongoing innovation in neurodegenerative diseases.
- Drug Mechanism and Effects: GT-02287 is an orally administered small molecule designed to restore the function of glucocerebrosidase (GCase) impaired in GBA1-associated and idiopathic Parkinson's disease, with preclinical studies showing improved GCase activity, reduced neuroinflammation, and protective effects on motor function.
- Clinical Trial Progress: Early Phase 1 clinical data indicate favorable safety and CNS exposure in healthy volunteers, with significant increases in GCase activity at therapeutic doses; the drug is currently being evaluated in a Phase 1b trial allowing treatment for up to 12 months in Parkinson's disease patients.
- Market Performance: GANX stock has traded between $1.41 and $4.34 over the past year, currently priced at $2.03, reflecting a 7.41% increase, indicating positive market sentiment towards its drug development progress.
See More
Gain Therapeutics Updates on GT-02287 for Parkinson's Disease
- Clinical Trial Progress: Gain Therapeutics is currently conducting a Phase 1b clinical trial for GT-02287 across seven sites in Australia, primarily assessing its safety and tolerability in Parkinson's disease patients, which is expected to provide crucial data for the drug's market potential.
- Innovative Drug Mechanism: As an orally administered small molecule, GT-02287 restores enzyme function impaired by GBA1 gene mutations, with preliminary data showing significant improvements in motor function and behavioral performance in animal models, indicating a potential disease-modifying effect.
- Funding Support: The project has received funding from The Michael J. Fox Foundation and other organizations, highlighting its recognition in Parkinson's disease treatment research and potentially accelerating clinical progress.
- International Conference Participation: The company will present an oral update on GT-02287 at the International GBA1 Meeting on May 22-23, 2026, further enhancing its visibility and influence in the biotechnology sector.
See More
Gain Therapeutics Reports FY EPS Beat
- Earnings Performance: Gain Therapeutics reported a FY GAAP EPS of -$0.61, beating expectations by $0.03, indicating gradual financial improvement despite ongoing challenges.
- Cash Position: As of December 31, 2025, the company held $20.8 million in cash, cash equivalents, and marketable securities, doubling from $10.4 million a year earlier, showcasing significant progress in financial management.
- Market Reaction: Although still in a loss position, the earnings beat may boost investor confidence, likely leading to a positive impact on stock price and attracting more attention and investment.
- Future Outlook: With increased cash reserves, Gain Therapeutics is positioned to enhance R&D investments, driving the development and marketing of new drugs, thereby strengthening its competitive edge in the biopharmaceutical sector.
See More
GAIN THERAPEUTICS INC Reports $20.2 Million Net Loss for 2025, Equivalent to $0.61 Per Share
- Financial Performance: Gain Therapeutics reported a net loss of $20.2 million for the year 2025, equating to a loss of $0.61 per share.
- Market Impact: The financial results may influence investor sentiment and the company's stock performance in the upcoming quarters.
See More
Gain Therapeutics Attends J.P. Morgan Healthcare Conference to Showcase GT-02287
- Conference Participation: Gain Therapeutics will attend several key forums during the J.P. Morgan Healthcare Conference from January 11 to 14, showcasing its latest advancements in Parkinson's disease treatment to enhance its visibility in the biotech industry.
- Drug Development: The lead drug candidate GT-02287 is currently undergoing a Phase 1b clinical trial primarily assessing its safety and tolerability in Parkinson's patients, which is expected to lay the groundwork for future market introduction.
- Funding Support: Gain's GT-02287 program has received funding from The Michael J. Fox Foundation and the European Union, indicating its development potential and market recognition, which may accelerate clinical progress.
- Technology Platform: Gain leverages its advanced Magellan™ platform to expedite drug discovery, focusing on developing treatments for neurodegenerative diseases, showcasing the company's innovative capabilities in the biotech sector.
See More
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
See More
